Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
Open Access
- 1 August 1990
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 86 (2) , 651-659
- https://doi.org/10.1172/jci114757
Abstract
The pharmacodynamics of intravenous bolus injections of 0.05, 0.10, 0.15, and 0.20 mg/kg of F(ab')2 fragments of the murine monoclonal antibody 7E3, 7E3-F(ab')2, directed against the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor of human platelets, were studied in groups of four patients with unstable angina pectoris. With 0.20 mg/kg, the template bleeding time prolonged from 6.3 +/- 1.9 (mean +/- SD) to greater than 30 min; it subsequently decreased to 13 +/- 7.8 min after 12 h and to 8.3 +/- 1.5 min after 24 h. The number of unblocked GPIIb/IIIa receptors (preinfusion value, 32,000 +/- 3,000 per platelet) decreased to 13 +/- 7% of the preinfusion value 1 h after infusion, and then increased to 33 +/- 10% at 12 h, 44 +/- 8% at 24 h and 67 +/- 7% at 72 h. The logarithm of the bleeding time was inversely proportional with the residual GPIIb/IIIa receptors (r = 0.73, P less than 0.0001). ADP-induced platelet aggregation (measured by changes in light transmittance in percent) decreased from 60 +/- 5% before infusion to 1.5 +/- 3% 1 h after infusion; it then increased to 29 +/- 3% after 24 h and 39 +/- 6% after 72 h. Platelet counts decreased by 16% at 1 h and returned to control values within 24 h. Proportionally smaller effects were seen at lower doses of 7E3-F(ab')2. Antibody injection did not induce spontaneous bleeding. Angina was not observed during the first 12 h when the bleeding time was significantly prolonged, but occurred in 6 of the 16 patients within the next 3 d. 2 of the 16 patients developed low titers of IgG antibodies specific for 7E3-F(ab')2. Thus 7E3-F(ab')2 induces dose-related inhibition of platelet function; at a dose of 0.20 mg/kg, it causes profound inhibition of platelet aggregation and prolongation of the bleeding time, but no spontaneous bleeding.This publication has 19 references indexed in Scilit:
- Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.Journal of Clinical Investigation, 1988
- Monoclonal antibody[mdash ]induced inhibition of platelet function: Effects on hemostasis and vascular graft thrombosis in baboonsJournal of Vascular Surgery, 1988
- A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.Circulation, 1987
- Platelet Reactivity in Unstable Coronary Artery DiseaseThrombosis and Haemostasis, 1987
- ANTITHROMBOTIC EFFECT OF A MONOCLONAL-ANTIBODY TO THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN AN EXPERIMENTAL ANIMAL-MODEL1986
- Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi‐Jewish and Arab populations of Israel: comparison of techniques for carrier detectionBritish Journal of Haematology, 1986
- A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.Journal of Clinical Investigation, 1985
- INHIBITION OF DOG PLATELET-FUNCTION BY INVIVO INFUSION OF F(AB')2 FRAGMENTS OF A MONOCLONAL-ANTIBODY TO THE PLATELET GLYCOPROTEIN-IIB/IIIA RECEPTOR1985
- The coronary thrombus: Its origin and fateHuman Pathology, 1971
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957